The frequencies of adverse reactions are ranked according to the following: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10000 to < 1/1000); very rare (< 1/10000).
Immune system disorders: Rare: hypersensitivity.
Metabolism and nutrition disorders: Uncommon: hyperglycaemia, gout.
Nervous system disorders: Uncommon: dizziness, dysgeusia, headache.
Vascular disorders: Uncommon: hypotension.
Respiratory thoracic and mediastinal disorders: Uncommon: epistaxis.
Gastrointestinal disorders: Common: gastrointestinal disorders (including abdominal distension, abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, eructation, gastro-oesophageal reflux disease, nausea or vomiting).
Uncommon: gastrointestinal haemorrhage.
Hepatobiliary disorders: Rare: liver disorders (including transaminases increased, alanine aminotransferase increased and aspartate aminotransferase increased).
Skin and subcutaneous tissue disorders: Uncommon: rash.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.